Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03099356 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv16
  2. Enrollment target: 19 to 22v15
  3. Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: Dec 2025 to Dec 2026
    v14
  4. Primary completion date: May 2024 to Dec 2024
    • Study completion date: May 2025 to Dec 2025
    v13
  5. Primary completion date: Dec 2023 to May 2024
    • Study completion date: Dec 2024 to May 2025
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary completion date: Jun 2023 to Dec 2023
    • Study completion date: Jun 2024 to Dec 2024
    v11
  2. Primary completion date: Dec 2022 to Jun 2023
    • Study completion date: Dec 2023 to Jun 2024
    v10
  3. Primary completion date: May 12, 2022 to Dec 2022
    • Study completion date: May 12, 2023 to Dec 2023
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Trial status: Suspended to Recruiting
    • Site details revised
    v7
  6. Trial status: Recruiting to Suspended Sponsor's reason: Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a…
    • Site details revised
    v6
  7. Re-verified, no change to tracked fieldsv5
  8. Study Status, Eligibilityv4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 12, 2017 to Apr 27, 2017
    • Site details revised
    v3
  10. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
Trial Details
NCT Number NCT03099356
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Metastatic Thyroid Cancer
Related terms Thyroid Neoplasms
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov